David A. Barbie

23.8k total citations · 2 hit papers
81 papers, 5.0k citations indexed

About

David A. Barbie is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, David A. Barbie has authored 81 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 32 papers in Molecular Biology and 30 papers in Immunology. Recurrent topics in David A. Barbie's work include Cancer Immunotherapy and Biomarkers (14 papers), interferon and immune responses (12 papers) and Lung Cancer Research Studies (12 papers). David A. Barbie is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), interferon and immune responses (12 papers) and Lung Cancer Research Studies (12 papers). David A. Barbie collaborates with scholars based in United States, Japan and Germany. David A. Barbie's co-authors include Russell W. Jenkins, Keith T. Flaherty, Brian K. Kennedy, Ed Harlow, Jiyong Zhao, Jonathan A. Fletcher, A. Gregory Matera, Brandon D. Lawrence, Shunsuke Kitajima and Nicholas J. Dyson and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David A. Barbie

78 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of resistance to immune checkpoint inhibitors

2018 999 citations Russell W. Jenkins, David A. Barbie et al. profile →
NPAT links cyclin E–Cdk2 to the regulation of replication-dependent histone gene transcription

2000 552 citations Jiyong Zhao, Brian K. Kennedy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Barbie United States	30	2.7k	2.2k	1.4k	630	628	81	5.0k
Michael Hölzel Germany	33	2.2k 0.8×	1.7k 0.8×	1.3k 0.9×	443 0.7×	588 0.9×	96	4.3k
Serenella M. Pupa Italy	35	2.3k 0.8×	2.3k 1.0×	1.5k 1.1×	442 0.7×	833 1.3×	94	4.8k
János L. Tanyi United States	36	1.9k 0.7×	1.7k 0.8×	887 0.6×	378 0.6×	720 1.1×	113	3.9k
Zachary A. Cooper United States	34	2.6k 1.0×	2.6k 1.2×	1.3k 0.9×	473 0.8×	623 1.0×	77	4.8k
Daniele V. F. Tauriello Netherlands	19	2.3k 0.8×	3.0k 1.4×	1.2k 0.8×	571 0.9×	1.1k 1.7×	34	4.9k
Jennifer L. Hsu United States	29	2.7k 1.0×	2.4k 1.1×	1.7k 1.2×	791 1.3×	1.3k 2.1×	62	5.1k
Thinle Chodon United States	22	3.3k 1.2×	3.2k 1.4×	1.4k 1.0×	422 0.7×	461 0.7×	33	5.2k
Suchit Jhunjhunwala United States	23	2.4k 0.9×	1.7k 0.8×	2.2k 1.5×	496 0.8×	825 1.3×	38	4.5k
Juanita Lopez United Kingdom	28	1.9k 0.7×	2.6k 1.2×	1.2k 0.9×	1.3k 2.0×	821 1.3×	144	4.9k
Anushka Dongre United States	11	2.0k 0.7×	1.8k 0.8×	764 0.5×	485 0.8×	1.2k 1.8×	15	3.8k

Countries citing papers authored by David A. Barbie

Since Specialization

Citations

This map shows the geographic impact of David A. Barbie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Barbie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Barbie more than expected).

Fields of papers citing papers by David A. Barbie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Barbie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Barbie. The network helps show where David A. Barbie may publish in the future.

Co-authorship network of co-authors of David A. Barbie

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Barbie. A scholar is included among the top collaborators of David A. Barbie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Barbie. David A. Barbie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cambria, Elena, Adriana Blazeski, Eunkyung Ko, et al.. (2025). A Vascular Microphysiological Model of Lung Fibrosis Reveals That Myofibroblasts and IPF Patient‐Derived Fibroblasts Impair Angiogenesis and Vasculogenesis. Advanced Functional Materials.

Murayama, Takahiko, Navin R. Mahadevan, Catherine B. Meador, et al.. (2024). Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer. Cancer Research Communications. 4(9). 2399–2414. 10 indexed citations

Wan, Zhengpeng, Shun Zhang, Liling Xu, et al.. (2024). Transmural Flow Upregulates PD‐L1 Expression in Microvascular Networks. Advanced Science. 11(26). e2400921–e2400921. 3 indexed citations

Nguyen, Huu Tuan, Mouhita Humayun, Nadia Gurvich, et al.. (2024). Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R. Biomaterials. 312. 122731–122731. 17 indexed citations

Kim, Dae Joong, Piotr Przanowski, Sanchita Bhatnagar, et al.. (2023). Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors. Nature Communications. 14(1). 2122–2122. 12 indexed citations

Nardi, Francesca, Naiara Perurena, Amy E. Schade, et al.. (2023). Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Journal of Clinical Investigation. 133(16). 12 indexed citations

Wang, Yufei, Alicia Buck, Brandon Piel, et al.. (2023). 442 CAIX targeted CAR-T cells exhibited antitumor efficacy on renal cell carcinoma (RCC) patient derived organotypic tumor spheroids (PDOTS). SHILAP Revista de lepidopterología. A491–A491. 1 indexed citations

Wan, Zhengpeng, Shun Zhang, Mark F. Coughlin, et al.. (2022). A Robust Method for Perfusable Microvascular Network Formation In Vitro. Small Methods. 6(6). e2200143–e2200143. 39 indexed citations

Goliaei, Bahram, Amir Reza Aref, Jochen H. Lorch, et al.. (2022). Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells. 11(22). 3534–3534. 3 indexed citations

10.

Wan, Zhengpeng, Mark F. Coughlin, Shun Zhang, et al.. (2022). New Strategy for Promoting Vascularization in Tumor Spheroids in a Microfluidic Assay. Advanced Healthcare Materials. 12(14). e2201784–e2201784. 53 indexed citations

11.

Hong, Deli, Erik H. Knelson, Yixiang Li, et al.. (2021). Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer Research. 82(2). 248–263. 25 indexed citations

12.

Wan, Zhengpeng, Shun Zhang, Sarah E. Shelton, et al.. (2021). A robust vasculogenic microfluidic model using human immortalized endothelial cells and Thy1 positive fibroblasts. Biomaterials. 276. 121032–121032. 31 indexed citations

13.

Zhu, Zehua, Tran C. Thai, Navin R. Mahadevan, et al.. (2019). Phosphorylation of RAB7 by TBK1/IKKϵ Regulates Innate Immune Signaling in Triple-Negative Breast Cancer. Cancer Research. 80(1). 44–56. 44 indexed citations

14.

Li, Fengkai, Shunsuke Kitajima, Susumu Kohno, et al.. (2019). Retinoblastoma Inactivation Induces a Protumoral Microenvironment via Enhanced CCL2 Secretion. Cancer Research. 79(15). 3903–3915. 67 indexed citations

15.

Farago, Anna F., B.Y. Yeap, Rebecca S. Heist, et al.. (2019). OA15.01 Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer: Updated Results from Phase 1/2 Clinical Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 1 indexed citations

16.

Kitajima, Shunsuke, Elena V. Ivanova, Sujuan Guo, et al.. (2018). Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discovery. 9(1). 34–45. 348 indexed citations

17.

Lizotte, Patrick H., Ruey‐Long Hong, Troy A. Luster, et al.. (2018). A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research. 6(12). 1511–1523. 69 indexed citations

18.

Yang, Shenghong, Yu Imamura, Russell W. Jenkins, et al.. (2016). Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation. Cancer Immunology Research. 4(6). 520–530. 76 indexed citations

19.

Barbie, David A., Brian A. Kudlow, Richard L. Frock, et al.. (2003). Nuclear Reorganization of Mammalian DNA Synthesis Prior to Cell Cycle Exit. Molecular and Cellular Biology. 24(2). 595–607. 30 indexed citations

20.

Ogryzko, Vasily, Tazuko Hirai, Valya Russanova, David A. Barbie, & Bruce H. Howard. (1996). Human Fibroblast Commitment to a Senescence-Like State in Response to Histone Deacetylase Inhibitors Is Cell Cycle Dependent. Molecular and Cellular Biology. 16(9). 5210–5218. 215 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact